Compare BridgeBio Pharma Inc (BBIO) vs Duolingo Inc (DUOL) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

DUOL trades at $130.9, up 6.79% in 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates at $0.66 versus $0.604 expected, driven by 23% daily active user growth. However, a lower Q3 revenue forecast has tempered optimism. Fundamentals show robust revenue growth to $1.04B in 2025 and a net income margin of 35.87%, though valuation multiples like P/E of 15.47 and P/S of 5.6 suggest premium pricing.

Outlook is mixed: strong user engagement and profitability support upside, but monetization concerns and competitive pressures pose risks. Analysts are cautious with a $121 consensus price target below current levels, highlighting execution challenges in converting growth to sustained revenue.